Is MORF or QYLD a better dividend investment in 2026?

MORF currently yields 3.51% with a 5% 5-year dividend growth rate. QYLD yields 12.24% with -2.1% growth. The better choice depends on your goal: QYLD offers higher current income.

What is the dividend yield difference between MORF and QYLD?

MORF has a forward dividend yield of 3.51% ($2.00/share annually). QYLD yields 12.24% ($2.04/share annually). The yield gap is 8.73 percentage points.

Home › Compare › MORF vs QYLD

MORF vs QYLD: Dividend Comparison 2026

MORF yields 3.51% · QYLD yields 12.24%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 QYLD wins by $1.5K in total portfolio value· pulled ahead in Year 10

INVESTMENT

TIME HORIZON10 years

MORF

● Live price

3.51%

Share price

$56.99

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.1K

Annual income

$439.80

Full MORF calculator →

QYLD

Global X Nasdaq 100 Covered Call ETF

● Live price

12.24%

Share price

$16.70

Annual div

$2.04

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$26.5K

Annual income

$6,038.84

Full QYLD calculator →

Portfolio growth — MORF vs QYLD

📍 QYLD pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	MORF	QYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, MORF + QYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

MORF pays

QYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MORF

Annual income on $10K today (after 15% tax)

$298.30/yr

After 10yr DRIP, annual income (after tax)

$373.83/yr

QYLD

Annual income on $10K today (after 15% tax)

$1,040.82/yr

After 10yr DRIP, annual income (after tax)

$5,133.01/yr

At 15% tax rate, QYLD beats the other by $4,759.18/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MORF + QYLD for your $10,000?

MORF: 50%QYLD: 50%

100% QYLD50/50100% MORF

Portfolio after 10yr

$25.8K

Annual income

$3,239.32/yr

Blended yield

12.55%

📊

Analyst Conviction Gap

Where Wall Street is split right now

MORF

No analyst data

Price Target

$57.00

+0.0% upside vs current

Range: $57.00 — $57.00

Altman Z

60.9

Piotroski

2/9

QYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MORF buys

QYLD buys

No recent congressional trades found for MORF or QYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricMORFQYLD

Forward yield	3.51%	12.24% ✓
Annual dividend / share	$2.00	$2.04 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$25.1K	$26.5K ✓
Annual income after 10y	$439.80	$6,038.84 ✓
Total dividends collected	$4.0K	$28.5K ✓
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: MORF vs QYLD ($10,000, DRIP)

Year	MORF Portfolio	MORF Income/yr	QYLD Portfolio	QYLD Income/yr	Gap
1	$11,051	$350.94	$10,384	$1,224.49	+$667.00 → MORF
2	$12,187	$362.45	$10,900	$1,388.18	+$1.3K → MORF
3	$13,414	$373.56	$11,576	$1,590.76	+$1.8K → MORF
4	$14,737	$384.26	$12,447	$1,844.20	+$2.3K → MORF
5	$16,163	$394.55	$13,567	$2,164.97	+$2.6K → MORF
6	$17,699	$404.42	$15,003	$2,576.05	+$2.7K → MORF
7	$19,352	$413.88	$16,853	$3,110.04	+$2.5K → MORF
8	$21,129	$422.92	$19,251	$3,813.85	+$1.9K → MORF
9	$23,040	$431.56	$22,390	$4,756.08	+$650.00 → MORF
10← crossover	$25,092	$439.80	$26,548	$6,038.84	$1.5K → QYLD

MORF vs QYLD: Complete Analysis 2026

MORF — Stock

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Full MORF Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →

📬

Get this MORF vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MORF vs SCHD MORF vs JEPI MORF vs O MORF vs KO MORF vs MAIN MORF vs XYLD MORF vs JEPQ MORF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.